Poor
Not Aligned
Patient Risk:
Medium
Summary
Substantial portions of the extracted claims are unsupported or not assessable from the provided label sections, including multiple safety-critical eligibility/prohibition-style statements (active infection; Crohn’s/ulcerative colitis) that are not clearly grounded as contraindications in the cited material. Several quantitative/comparative efficacy and incidence claims are absent from the provided label content.
Category Scores
Accurate Statements
Taltz blocks interleukin-17A (IL-17A).
Supported by 12.1 (selectively binds IL-17A and inhibits its interaction with IL-17 receptor).
Taltz binds specifically to IL-17A.
Supported by 12.1 (selectively binds IL-17A cytokine).
Taltz prevents IL-17A from triggering immune responses that cause inflammation.
Partially supported: 12.1 describes inhibiting interaction and inhibiting release of proinflammatory cytokines and chemokines; does not explicitly phrase 'triggering immune responses' but directionally matches mechanism.
Taltz is IL-17 specific.
Supported by 12.1 and 11 DESCRIPTION (neutralizing activity/neutralization against IL-17A; selective binding to IL-17A).
Taltz is administered using pre-filled auto-injectors.
Supported by 11 DESCRIPTION (prefilled autoinjector) and 2.7 (training to self-inject using autoinjector or prefilled syringe).
Taltz treats moderate-to-severe plaque psoriasis in adults.
Supported by 1.1 (patients 6 years and older with moderate-to-severe plaque psoriasis candidates for systemic therapy or phototherapy).
Taltz treats moderate-to-severe plaque psoriasis in children aged 6 years and older.
Supported by 1.1 (indicated for 6 years of age and older).
Taltz treats active psoriatic arthritis.
Supported by 1.2.
Taltz treats active ankylosing spondylitis.
Supported by 1.3.
Taltz treats active non-radiographic axial spondyloarthritis.
Supported by 1.4 (objective signs of inflammation).
Taltz can cause fungal infections.
Supported by 5.1 (tinea infections occurred more frequently).
Taltz is associated with an increased chance of infections.
Supported by 5.1 (TALTZ may increase risk of infection; higher overall infection rate vs placebo).
Taltz is associated with inflammatory bowel disease flare-ups.
Supported by 5.5 (Crohn's disease and ulcerative colitis, including exacerbations).
Taltz can cause rare allergic reactions.
Partially supported: 5.3 describes serious hypersensitivity reactions (each ≤0.1% in trials) and postmarketing anaphylaxis, but does not use 'rare allergic reactions' wording.
Unsupported Statements
The FDA approved Taltz in 2016.
Approval year information is not provided in the supplied label sections.
Taltz was approved by the FDA in 2016 for plaque psoriasis in adults.
No FDA approval year information in the supplied label sections; only indications are provided.
Taltz was later approved for psoriatic arthritis.
No timing/'later approved' information is provided in the supplied label sections.
Taltz was later approved for ankylosing spondylitis.
No timing information provided in the supplied label sections.
Taltz was later approved for non-radiographic axial spondyloarthritis.
No timing information provided in the supplied label sections.
Taltz was later approved for hidradenitis suppurativa.
The provided label sections do not include a hidradenitis suppurativa indication.
Taltz prevents IL-17A from triggering immune responses that cause skin plaques.
Label supports IL-17A mechanism and plaque psoriasis indication, but does not explicitly state 'preventing IL-17A from triggering immune responses that cause skin plaques.'
Taltz prevents IL-17A from triggering immune responses that cause joint pain.
No label statement about 'joint pain' as an outcome of IL-17A inhibition is provided in the supplied sections.
Upper respiratory infections occur in about 20% of users of Taltz.
The supplied label sections do not provide a numeric '~20%' URTI rate.
Taltz can cause injection-site reactions.
No injection-site reactions are described in the supplied label sections.
Taltz can cause nausea.
No nausea adverse reaction information is provided in the supplied label sections.
Taltz increases the risk of tuberculosis.
Supplied label provides TB evaluation guidance and instruction not to administer to active TB, but does not explicitly say 'increases the risk of tuberculosis.'
Taltz is not for patients with active infections.
The supplied label language provides risk and TB-specific 'do not administer to patients with active TB infection,' but does not provide a general prohibition statement for all 'active infections' in the cited sections.
Taltz is not for patients with Crohn's disease or ulcerative colitis.
The supplied label warns of increased risk/exacerbations and instructs discontinuation if IBD occurs; it does not state Crohn's/ulcerative colitis is a 'not for' contraindicated population in the provided sections.
Taltz outperforms or matches Humira (adalimumab) in clearing psoriasis plaques.
Comparative efficacy vs Humira is not provided in the supplied label sections.
Taltz outperforms or matches Stelara (ustekinumab) in clearing psoriasis plaques.
Comparative efficacy vs Stelara is not provided in the supplied label sections.
In trials, Taltz had PASI 90 scores of 80%+ at week 12.
No PASI 90 or week 12 quantitative results are present in the supplied label sections.
Taltz is unlike TNF inhibitors such as Humira.
No TNF inhibitor comparison is present in the supplied label sections.
Taltz offers faster skin clearance than TNF inhibitors like Humira.
No comparative clearance speed information is present in the supplied label sections.
Taltz has similar joint efficacy to Humira in psoriatic arthritis.
No comparative joint efficacy data vs Humira is present in the supplied label sections.
Eli Lilly manufactures Taltz.
No manufacturer information is provided in the supplied label sections.
The list price of Taltz is around $6,400 per month in the U.S. (pre-discounts/insurance).
Pricing information is not included in the supplied label sections.
Patient assistance programs cap Taltz copays at $5/month for eligible insured patients.
No patient assistance/coplay cap information is provided in the supplied label sections.
Key U.S. patents cover the ixekizumab antibody and formulation.
No patent information is provided in the supplied label sections.
The key U.S. patents for Taltz expire between 2032 and 2036.
No patent expiry information is provided in the supplied label sections.
Biosimilar competition for Taltz is unlikely before 2034.
No biosimilar competition/timing information is provided in the supplied label sections.
Contradictions
High
AI Statement
Taltz was later approved for hidradenitis suppurativa.
Label Reference
1.1–1.4, 11, 2, 5 (provided sections do not include hidradenitis suppurativa indication).
Important Omissions
Boxed warning and formal contraindications text were not evaluated because the provided label excerpts do not include the label's Contraindications (Section 4) or Boxed Warning (if any). This limits verification of whether any of the safety/eligibility statements match contraindication-level wording.
Importance:
High
Drug interaction information and administration details beyond broad self-injection guidance (e.g., missed dose handling is present but not reflected in the extracted claims) were not covered; omitted because no interaction claims were made, but gaps remain for full label alignment assessment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Multiple extracted claims use strict prohibition phrasing ('not for patients with active infections' and 'not for patients with Crohn's disease or ulcerative colitis') that is not clearly supported as a contraindication-level statement in the provided label sections. Several safety-relevant adverse reaction/quantitative incidence claims are unsupported, and efficacy comparative statements are unsupported, which may mislead clinical decision-making relative to label-evidence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Safety-critical eligibility/prohibition-style claims are not supported as stated in the provided label excerpts (general 'active infections' prohibition; 'not for' Crohn's/UC), and multiple unsupported efficacy/quantitative/comparative claims are included.
Suggested Improvement
Remove or rephrase unsupported claims to match provided label wording; restrict assertions to sections explicitly supporting them (e.g., TB-specific 'do not administer to patients with active TB infection' rather than 'not for patients with active infections'; IBD guidance as increased risk/monitoring and discontinuation if IBD occurs rather than a contraindication-style statement). Exclude non-label details (pricing, patents, biosimilar timing, comparative performance, PASI 90 percentages, URTI ~20%, injection-site reactions, nausea) unless supported by provided label text.